| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Dr. Yujing Lim CEO | CXA Exchange | - ISIN |
| Australia Country | - Employees | - Last Dividend | 14 Mar 2024 Last Split | - IPO Date |
Osteopore Limited is a pioneering medical device company that specializes in the design, development, and marketing of bioresorbable implants for use in neurosurgical, orthopedic, and maxillofacial surgeries. The company stands out in the medical field for its innovative approach to bone regeneration, leveraging cutting-edge 3D printing technology and bioresorbable materials to create implants designed to support natural bone healing processes. Founded in 2003 and based in Singapore, Osteopore has extended its operations globally, including in Australia, marking its presence as an international player in biomedical engineering. In addition to its product offerings, Osteopore has also entered into strategic collaborations, such as with Livingstone Health Holding Limited, aimed at developing new applications and products that further the company's mission to enhance regenerative bone and tissue technologies.
This bioresorbable implant is a revolutionary product designed by Osteopore for use in neurosurgery. Specifically, Osteoplug is employed to cover trephination burr holes, which are created in the skull during surgical procedures. The implant serves an essential function by promoting bone regrowth in the trephination sites, ultimately dissolving into the body, thus eliminating the need for a second surgery to remove the implant.
Osteomesh is another bioresorbable implant produced by Osteopore, but its application is primarily in craniofacial surgery. This product is designed to repair various types of fractures, including those in the orbital floor, and to fill surgical defects. By providing a scaffold for bone regeneration, Osteomesh supports the body's natural healing processes, seamlessly integrating with the patient's bone structure over time and then safely resorbing into the body.